Search hospitals > Michigan > Troy
Michigan Institute of Urology-Town Center
Claim this profileTroy, Michigan 48084
Global Leader in Prostate Cancer
Global Leader in Cancer
Conducts research for Bladder Cancer
Conducts research for Breast Cancer
Conducts research for Lung Cancer
96 reported clinical trials
11 medical researchers
Summary
Michigan Institute of Urology-Town Center is a medical facility located in Troy, Michigan. This center is recognized for care of Prostate Cancer, Cancer, Bladder Cancer, Breast Cancer, Lung Cancer and other specialties. Michigan Institute of Urology-Town Center is involved with conducting 96 clinical trials across 134 conditions. There are 11 research doctors associated with this hospital, such as Dana Zakalik, Andrew A. Muskovitz, Joseph M. Anderson, and Faisal Musa.Area of expertise
1Prostate Cancer
Global LeaderStage IV
PSA
Gleason Score
2Cancer
Global LeaderStage IV
Stage II
Stage III
Top PIs
Dana ZakalikBeaumont Hospital - Farmington Hills1 year of reported clinical research
Expert in Cancer
Studies Ovarian Cancer
12 reported clinical trials
46 drugs studied
Andrew A. MuskovitzWilliam Beaumont Hospital-Royal Oak3 years of reported clinical research
Studies Cancer
Studies Colorectal Cancer
8 reported clinical trials
19 drugs studied
Joseph M. AndersonBeaumont Hospital - Dearborn9 years of reported clinical research
Studies Non-Small Cell Lung Cancer
Studies Lung Cancer
3 reported clinical trials
7 drugs studied
Faisal MusaBeaumont Hospital - Dearborn4 years of reported clinical research
Studies Adenocarcinoma
Studies Colorectal Cancer
3 reported clinical trials
10 drugs studied
Clinical Trials running at Michigan Institute of Urology-Town Center
Non-Small Cell Lung Cancer
Breast Cancer
Lung Cancer
Prostate Cancer
Ovarian Cancer
Bladder Cancer
Fallopian Tube Cancer
Peritoneal Cancer
Squamous Cell Carcinoma
Cancer
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Genetic Testing
for Early-Stage Lung Cancer
This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.
Recruiting0 awards N/A4 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Michigan Institute of Urology-Town Center?
Michigan Institute of Urology-Town Center is a medical facility located in Troy, Michigan. This center is recognized for care of Prostate Cancer, Cancer, Bladder Cancer, Breast Cancer, Lung Cancer and other specialties. Michigan Institute of Urology-Town Center is involved with conducting 96 clinical trials across 134 conditions. There are 11 research doctors associated with this hospital, such as Dana Zakalik, Andrew A. Muskovitz, Joseph M. Anderson, and Faisal Musa.